{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:20:16Z","timestamp":1787541616046,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09797-7","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:42:34Z","timestamp":1774338154000},"page":"3583-3593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"71","author":[{"given":"Andrew R.","family":"Roney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dupre","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armeen","family":"Barghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureya","family":"Hussani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivy","family":"Cusumano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley N.","family":"Limketkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny S.","family":"Sauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"9797_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238","author":"QA Guan","year":"2019","unstructured":"Guan QA. Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019. https:\/\/doi.org\/10.1155\/2019\/7247238.","journal-title":"J Immunol Res"},{"key":"9797_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet. 2017;389:1741\u20131755.","journal-title":"Lancet."},{"key":"9797_CR3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet (London, England). 2017;389:1756\u20131770.","journal-title":"Lancet (London, England)."},{"key":"9797_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet (London, England). 2002;359:1541\u20131549.","journal-title":"Lancet (London, England)."},{"key":"9797_CR5","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u20132476.","journal-title":"N Engl J Med."},{"key":"9797_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: The CLASSIC-I trial. Gastroenterology. 2006;130:323\u2013333.","journal-title":"Gastroenterology."},{"key":"9797_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Van Assche G, Reinisch W, Colombel J, D\u2019Haens G, Wolf DC et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.e3.","journal-title":"Gastroenterology."},{"key":"9797_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u2013238.","journal-title":"N Engl J Med."},{"key":"9797_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.e1.","journal-title":"Gastroenterology."},{"key":"9797_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11894-019-0669-6","volume":"21","author":"B Click","year":"2019","unstructured":"Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep. 2019;21:1.","journal-title":"Curr Gastroenterol Rep."},{"key":"9797_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","volume":"7","author":"G Mocci","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohn\u2019s Colitis. 2013;7:769\u2013779.","journal-title":"J Crohn\u2019s Colitis."},{"key":"9797_CR12","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet. 2002;359:1686\u20131689.","journal-title":"Lancet."},{"key":"9797_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123280","author":"MA Barbieri","year":"2022","unstructured":"Barbieri MA, Viola A, Cicala G, Spina E, Fries W. Effectiveness and safety profiles of biological therapies in inflammatory bowel disease: Real life data from an active pharmacovigilance project. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123280.","journal-title":"Biomedicines"},{"key":"9797_CR14","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.12998\/wjcc.v10.i18.6091","volume":"10","author":"H-H Yang","year":"2022","unstructured":"Yang H-H, Huang Y, Zhou X-C, Wang R-N. Efficacy and safety of adalimumab in comparison to infliximab for Crohn\u2019s disease: A systematic review and meta-analysis. World J Clin cases. 2022;10:6091\u20136104.","journal-title":"World J Clin cases."},{"key":"9797_CR15","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/apt.13808","volume":"44","author":"J Cosnes","year":"2016","unstructured":"Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C et al. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther. 2016;44:1102\u20131113.","journal-title":"Aliment Pharmacol Ther."},{"key":"9797_CR16","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/ibd\/izz001","volume":"25","author":"C Chen","year":"2019","unstructured":"Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25:1417\u20131427.","journal-title":"Inflamm Bowel Dis."},{"key":"9797_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/MIB.0000000000001072","volume":"23","author":"P Olivera","year":"2017","unstructured":"Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L. Treatment Persistence for Infliximab Versus Adalimumab in Crohn\u2019s Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017;23:976\u2013985.","journal-title":"Inflamm Bowel Dis."},{"key":"9797_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10620-019-05867-1","volume":"65","author":"YS Jung","year":"2020","unstructured":"Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci. 2020;65:1436\u20131444.","journal-title":"Dig Dis Sci."},{"key":"9797_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otab011","volume":"3","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, May M, Feig C, Straub V, Schmelz R. Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: A german retrospective claims data analysis. Crohn\u2019s Colitis 360 2021;3:1\u201311.","journal-title":"Crohn\u2019s Colitis 360"},{"key":"9797_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000503859","volume":"102","author":"A Mevius","year":"2021","unstructured":"Mevius A, Brandes A, Hardtstock F, Wilke T, Ratsch BA, Orzechowski HD et al. Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis. Digestion. 2021;102:216\u2013226.","journal-title":"Digestion."},{"key":"9797_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al. Medication compliance and persistence: Terminology and definitions. Value Heal. 2008;11:44\u201347.","journal-title":"Value Heal."},{"key":"9797_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/apt.12499","volume":"38","author":"R Panaccione","year":"2013","unstructured":"Panaccione R, Colombel JF, Sandborn WJ, D\u2019Haens G, Zhou Q, Pollack PF et al. Adalimumab maintains remission of Crohn\u2019s disease after up to 4 years of treatment: Data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38:1236\u20131247.","journal-title":"Aliment Pharmacol Ther."},{"key":"9797_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ibd.21697","volume":"18","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB et al. Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201\u2013211.","journal-title":"Inflamm Bowel Dis."},{"key":"9797_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ibd\/izx072","volume":"24","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW et al. Infliximab for Crohn\u2019s disease: More than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490\u2013501.","journal-title":"Inflamm Bowel Dis."},{"key":"9797_CR25","first-page":"680","volume":"11","author":"G D\u2019Haens","year":"2017","unstructured":"D\u2019Haens G, Reinisch W, Colombel JF, Panes J, Ghosh S, Prantera C et al. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn\u2019s Disease Treated With Infliximab [Remicade\u00ae] or Conventional Therapy. J Crohns Colitis. 2017;11:680\u2013689.","journal-title":"J Crohns Colitis."},{"key":"9797_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.crohns.2014.04.012","volume":"8","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn\u2019s disease. J Crohn\u2019s Colitis. 2014;8:1407\u20131416.","journal-title":"J Crohn\u2019s Colitis."},{"key":"9797_CR27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s10620-017-4465-6","volume":"63","author":"P Andrade","year":"2018","unstructured":"Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G. Anti-Tumor Necrosis Factor-\u03b1-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018;63:746\u2013754. https:\/\/doi.org\/10.1007\/s10620-017-4465-6","journal-title":"Dig Dis Sci."},{"key":"9797_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MEG.0000000000001917","volume":"33","author":"GB Nigam","year":"2021","unstructured":"Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2021;33:346\u2013357.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"9797_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cgh.2010.01.014","volume":"8","author":"GR Lichtenstein","year":"2010","unstructured":"Lichtenstein GR, Thomsen O, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R et al. Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn\u2019s Disease for up to 18 Months. Clin Gastroenterol Hepatol. 2010;8:600\u2013609.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9797_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","volume":"6","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel J-F. Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644\u2013653.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9797_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12624","volume":"39","author":"CJM Williams","year":"2014","unstructured":"Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: Malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447\u2013458.","journal-title":"Aliment Pharmacol Ther."},{"key":"9797_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","volume":"14","author":"J Axelrad","year":"2016","unstructured":"Axelrad J, Bernheim O, Colombel J-F, Malerba S, Ananthakrishnan A, Yajnik V et al. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016;14:58\u201364.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9797_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","volume":"22","author":"A Gupta","year":"2024","unstructured":"Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2024;22:499-512.e6.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9797_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153824","author":"A Massano","year":"2023","unstructured":"Massano A, Bertin L, Zingone F, Buda A, Visaggi P, Bertani L et al. Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153824.","journal-title":"Cancers (Basel)"},{"key":"9797_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10620-017-4465-6","volume":"67","author":"O Ledder","year":"2022","unstructured":"Ledder O. The Question That Doesn\u2019t Seem to Go Away: Cancer Risk of Anti-TNF Therapy. Dig Dis Sci. 2022;67:6\u20137. https:\/\/doi.org\/10.1007\/s10620-017-4465-6","journal-title":"Dig Dis Sci."},{"key":"9797_CR36","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","volume":"31","author":"R Panaccione","year":"2010","unstructured":"Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D\u2019Haens GR, Robinson AM et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn\u2019s disease. Aliment Pharmacol Ther. 2010;31:1296\u20131309.","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09797-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09797-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09797-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:00:41Z","timestamp":1787540441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09797-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9797"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09797-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by our center\u2019s Institutional Review Board. As this was a retrospective chart review of de-identified data, the requirement for informed consent was waived in accordance with institutional policy. All data were handled in compliance with institutional guidelines for confidentiality and privacy, and no protected health information was disclosed","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}